Navigation Links
Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial
Date:2/11/2008

MELBOURNE, Australia, Feb. 11 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH; AIM: PSG; OTCQX: PPGNY) and Nestle Nutrition (Nestle) today announced that their joint phase 2 human clinical trial to establish the efficacy of Phosphagenics' Phospha E(R) in the management of metabolic syndrome is advancing at three sites in Adelaide, Australia.

Based on current recruitment rates of study participants, the double-blind phase 2 trial, which is fully funded by Nestle, is expected to be completed in mid-2008.

This phase 2 clinical trial follows two pre-clinical dose response trials completed by Nestle and Phosphagenics in 2006. The results of those studies confirmed that, when given orally, Phospha E(R) significantly reduces many of the key biomarkers associated with metabolic syndrome.

Metabolic syndrome is characterized by a group of risk factors that increase the risk of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls.

The companies have agreed on the principal terms of a commercialization agreement, which will grant a worldwide exclusive license to Nestle for the use of Phospha E(R) in medical foods and for Phosphagenics to be the exclusive manufacturer and supplier of Phospha E(R) to Nestle. The final commercial agreement is due to be signed upon completion of the phase 2 trial.

Harry Rosen, President & CEO of Phosphagenics said: "We believe the agreed terms will deliver value to all parties and we look forward to building on the already strong relationship we have with Nestle, the world's largest food company."

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' core technology is built around t
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...l Results from prior U.S., U.K. and China Trials ,...apies, Inc. (VTI), a development stage company tar...llment has begun for a randomized, controlled, mul...the Extracorporeal Liver Assist Device (ELAD) as a...ALF) under three protocols. The study is open for ...
(Date:1/6/2009)...Newswire/ -- Cequent Pharmaceuticals, a pioneer in...-based treatments to prevent and treat human disea...ted a successful toxicology study of its candidate...ic targeting the primary oncogene (beta-catenin, C...P is an inherited gastrointestinal disease that ca...
(Date:1/5/2009)... Women undergoing in vitro,fertil...elp support early,pregnancy, but the intramuscula...n be painful for patients. Formulations of proges...bcutaneous injection or vaginal suppository may of.... , With patient well-being a constant focu...
(Date:12/27/2008)...27 According to the latest,scienc...ume modest doses of,resveratrol plus an array of ...to 5 glasses of aged, red wine, rather than resver....com/cgi-bin/prnh/20080603/LATU039 ) , The...ne fails to prolong,the life of laboratory mice. ...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3Live Christmas Trees Can Trigger Mold Allergies 6510 1Live Christmas Trees Can Trigger Mold Allergies 6510 2Live Christmas Trees Can Trigger Mold Allergies 6510 3Geisinger rheumatologists redesign osteoporosis rheumatoid arthritis care 6507 1Geisinger rheumatologists redesign osteoporosis rheumatoid arthritis care 6507 2Update 3A Oscar Nominated Actress Signs on as Neutrogena 28R 29 Brand Ambassador 6505 1Update 3A Oscar Nominated Actress Signs on as Neutrogena 28R 29 Brand Ambassador 6505 2Continental Airlines Sponsors Golfers Against Cancer Tournament 6502 1
...-(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScienc...armaceutical,company, discussed results from two p...otherapy induced angiogenesis and,rationale for co...,Suspension (paclitaxel protein-bound particles fo...F inhibitor drugs like,bevacizumab (Avastin(R)) at...
...-(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScienc...armaceutical,company, announced results from two p... (secreted protein acidic and rich in,cysteine) ex...in-bound (nab(TM)) tumor-targeting technology at t...AACR) Annual Meeting held,April 14-18, 2007 in Los...
Other Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5
(Date:1/8/2009)...ole introduces Senator Daschle at his confirmation...man Services , , , WASHINGTON, Jan. 8 /PRNews... founding board member Senator Tom Daschle, nomine...etary, was introduced by fellow BPC founder and fr...today. The hearing was convened by the Senate Heal...
(Date:1/8/2009)...at St. Jude Children,s Research Hospital have demo...pneumonia following influenza. They found that the...ill bacteria by inhibiting their protein synthesis...eatment with the "beta-lactam" antibiotic ampicill... , The finding is important because pneumonia, r...
(Date:1/8/2009)...RANCISCO, Jan. 8 Medivat...David Hung, M.D., president and chief,executive o...n Healthcare,Conference on Wednesday, January 14,...ncis Hotel in San Francisco. , Dr. Hung wil...al,development programs for Dimebon for Alzheimer...
(Date:1/8/2009)...a., Jan. 8 Cephalon, In...aldino, Jr., Ph.D., Chairman and CEO will present...eld on January 13, 2009 in San Francisco, CA at ap... Time). The presentation will be webcast live on t...site. , , The webcast will be archived for one...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...phy from Newfoundland has been charged of intentio...positive woman who has pleaded guilty against a se...ressed that she did not sexually assault any soldi...ve asked its official to undergo medical tests if ...
...onclave will be opened by India’s Health Minister ...ave will review the progress made towards achievin...h. The conclave is expected to make recommendation...a for achieving the goals, according to the Confed...
...g revelation, a recent survey by the Confidential ...dicates that there are at least 50 cases // a year...pts. The systematic investigation by CEMACH, whic...of Britain's six royal colleges of medicine, comes...
... a latest survey, there is a steady decline in the... Britain // . The findings were presented at the ...th of this month by researchers from Cancer Resear...n of Cancer Registries. The survey revealed, that...
Other Medicine News:
...hip Camera System offers 800+ lines of resolution ...ic gain control, and white balance features in a u...stem for Microscopic Application, Domestic (MS 100...CCU) with power cord and video cables , (MS 1000-0...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides a combination of concentrated cold / hot and compression for the neck
Provides a combination of concentrated cold / hot and compression for the ankle
Medicine Products: